BBIO Investors - Our Quick Report For You.

By Chris Stiles • Monday, October 30 15:38 • Permanent Link

BridgeBio Pharma logged a 4.5% change during today's afternoon session, and is now trading at a price of $25.55 per share. The S&P 500 index moved 1.0%. BBIO's trading volume is 803,067 compared to the stock's average volume of 1,705,529.

BridgeBio Pharma trades -44.94% away from its average analyst target price of $46.4 per share. The 10 analysts following the stock have set target prices ranging from $33.0 to $60.0, and on average have given BridgeBio Pharma a rating of buy.

Anyone interested in buying BBIO should be aware of the facts below:

BridgeBio Pharma has moved 145.0% over the last year, and the S&P 500 logged a change of 9.0%
Based on its trailing earnings per share of -3.75, BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -6.8 while the S&P 500 average is None
BBIO has a forward P/E ratio of -9.0 based on its forward 12 month price to earnings (EPS) of $-2.83 per share
The company has a price to earnings growth (PEG) ratio of 0.12 — a number near or below 1 signifying that BridgeBio Pharma is fairly valued compared to its estimated growth potential
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
Based in Palo Alto, the company has 392 full time employees and a market cap of $4.15 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.